iCAD (ICAD) Status Update summary

Strategic rationale and vision

• Acquisition of iCAD aims to accelerate AI-driven breast cancer solutions, expanding reach to 10 million annual mammograms across 1,700 provider sites in over 50 countries.

• The combined entity will offer the most comprehensive portfolio of breast imaging AI solutions, enhancing early cancer detection, workflow efficiency, and patient outcomes.

• The deal is expected to drive industry consolidation, stabilize the AI space in breast imaging, and position the company as a leader in radiology AI.

• Integration will strengthen commercialization capabilities and expand access to advanced AI tools for radiologists.

• iCAD's commercial and engineering teams will join DeepHealth, accelerating innovation and product development.

Financial impact and guidance

• The transaction is a stock-for-stock deal, valuing iCAD at $103 million, with an enterprise value of $85 million after accounting for cash.

• iCAD stockholders will receive 0.0677 shares of RadNet common stock for each iCAD share held at closing.

• iCAD adds nearly $20 million in revenue based on 2024 actuals; positive adjusted EBITDA run rate is expected by end of 2026 through $7 million+ in cost synergies.

• 2025 guidance for DeepHealth remains at $80–$90 million revenue and $15–$17 million adjusted EBITDA, with iCAD contributing $4–$5 million revenue post-close.

• The deal is expected to close in Q2 or Q3 2025, subject to iCAD stockholder approval and customary conditions.

Operational and product synergies

• Integration brings 66 iCAD employees, filling key commercial and R&D roles, and accelerates hiring plans for DeepHealth.

• Product synergies include immediate availability of a broader AI portfolio, multi-system compatibility, and future risk assessment tools.

• Commercial synergies target upselling advanced AI solutions to iCAD’s installed base and leveraging global distribution channels.

• Expanded product offerings will include breast cancer detection, risk evaluation, density assessment, and arterial calcification analysis.

• Both companies expect to realize synergies and drive further innovation in diagnostic imaging.